Figure 4
Figure 4. CRP and convulxin (CVX) activation of Bdkrb2−/− platelets. CRP (0.01 to 1 μg/mL) or CVX (0.1 to 5 nM) stimulated integrin activation (JON/A binding) (A) or P-selection expression (B) in wild-type (Bdkrb2+/+) and Bdkrb2−/− platelets. The data represent the mean ± SEM of at least 4 separate experiments with 3 or more platelet samples from each genotype. CRP (0.1 to 1 μg/mL) stimulated integrin activation (JON/A) (C) or P-selection expression (D) in platelets from wild-type (Bdkrb2+/+) (n = 6), Bdkrb2−/− (n = 6), or Bdkrb2−/− in vivo treated with A-779 (n = 7). The data represent the mean ± SEM. CRP (0.1 to 1.0 μg/mL) induced integrin activation (E) and P-selectin expression (F) in platelets from wild-type (Bdkrb2+/+), Bdkrb2−/−, or Bdkrb2−/− treated with nimesulide by gavage for 10 days. The data represent the mean ± SEM of at least 5 animals in each group from 3 independent experiments. *P < .05. MFI, mean fluorescent intensity.

CRP and convulxin (CVX) activation of Bdkrb2−/− platelets. CRP (0.01 to 1 μg/mL) or CVX (0.1 to 5 nM) stimulated integrin activation (JON/A binding) (A) or P-selection expression (B) in wild-type (Bdkrb2+/+) and Bdkrb2−/− platelets. The data represent the mean ± SEM of at least 4 separate experiments with 3 or more platelet samples from each genotype. CRP (0.1 to 1 μg/mL) stimulated integrin activation (JON/A) (C) or P-selection expression (D) in platelets from wild-type (Bdkrb2+/+) (n = 6), Bdkrb2−/− (n = 6), or Bdkrb2−/− in vivo treated with A-779 (n = 7). The data represent the mean ± SEM. CRP (0.1 to 1.0 μg/mL) induced integrin activation (E) and P-selectin expression (F) in platelets from wild-type (Bdkrb2+/+), Bdkrb2−/−, or Bdkrb2−/− treated with nimesulide by gavage for 10 days. The data represent the mean ± SEM of at least 5 animals in each group from 3 independent experiments. *P < .05. MFI, mean fluorescent intensity.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal